News
Zacks Investment Research on MSN15h
RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman SyndromeUltragenyx Pharmaceuticals RARE announced that the FDA has granted the Breakthrough Therapy designation to its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback